PMEF
LFCR icon

Point72 Middle East FZE’s Lifecore Biomedical LFCR Stock Holding History

Point72 Middle East FZE’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-930
Closed -$6.03K – 1948
2022
Q4 		$6.03K Buy
+930
New +$7.67K ﹤0.01% 1765

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Point72 Middle East FZE's LFCR Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 930 shares — an estimated $6.03K sold.

Point72 Middle East FZE first reported a position in LFCR in Q4 2022 and held it in 1 quarter. The position peaked at $6.03K in Q4 2022. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 930 Lifecore Biomedical shares in Q1 2023, an estimated $6.03K.
  • Point72 Middle East FZE first reported a position in Lifecore Biomedical in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Lifecore Biomedical position peaked at $6.03K in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.